Table 2. mVIM and mCCNA1 performance in esophageal balloon samples.

VIM and CCNA1 gene methylation was assayed in DNA samples from non-endoscopic balloon sampling of the distal esophagus from: Unaffected controls (individuals with GERD, erosive esophagitis, or no pathology detected during endoscopy); cases of nondysplastic Barrett’s esophagus (NDBE), further subclassified as short-segment Barrett’s esophagus of 1–3 cm (SSBE) or long-segment Barrett’s esophagus of ≥ 3 cm (LSBE); Barret’s esophagus with low-grade dysplasia (LGD); Barrett’s esophagus with high-grade dysplasia (HGD); esophageal adenocarcinoma and/or junctional cancer of the esophagus (EAC). Samples were scored as VIM methylated for mVIM >1.0%, and as CCNA1 methylated for mCCNA1 >1.0%, (using ROC defined cutpoints from Fig. 6). Samples were positive for the panel of mCCNA1 plus mVIM if either marker tested positive. Entries indicate percent sensitivity or specificity (%) and total number of individuals tested (n). We note that only 4 HGD were studied, and in this small sample size differences in the rate of mVIM and mCCNA1 detection of HGD versus detection of NBDE or EAC are not statistically significant (P>0.088 for any between group comparison).

	mVIM		mCCNA1		Either mVIM or mCCNA1
	%	n	%	n	%	n
Specificity unaffected controls	91.7%	36	100.0%	36	91.7%	36
Sensitivity all cases	80.0%	50	72.0%	50	88.0%	50
Sensitivity all NDBE	80.6%	31	71.0%	31	90.3%	31
Sensitivity SSBE	69.2%	13	53.8%	13	84.6%	13
Sensitivity LSBE	88.9%	18	83.3%	18	94.4%	18
Sensitivity all dysplastic BE	72.7%	11	72.7%	11	81.8%	11
Sensitivity LGD	83.3%	6	100.0%	6	100.0%	6
Sensitivity HGD	50.0%	4	50.0%	4	50.0%	4
Sensitivity EAC	87.5%	8	75.0%	8	87.5%	8